Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) is a biotechnology leader pioneering RNA-targeted therapies through its antisense technology platform. This news hub provides investors and industry professionals with comprehensive updates on the company's clinical developments, strategic partnerships, and regulatory milestones.
Access real-time updates on Ionis' innovative research in neurology, cardiology, and rare diseases, including progress on therapies like Qalsody and Wainua. The page aggregates essential information including earnings reports, collaboration announcements with partners such as Biogen and AstraZeneca, and clinical trial outcomes.
Our curated collection serves as your primary source for tracking Ionis' advancements in antisense oligonucleotide development and commercialization strategies. Bookmark this page for streamlined access to verified updates about licensing agreements, patent developments, and therapeutic pipeline expansions.
Ionis Pharmaceuticals (Nasdaq: IONS) will hold its 2022 virtual Annual Meeting of Stockholders on June 2, 2022. The schedule includes a brief stockholder meeting at 5:00 p.m. ET, where eligible stockholders can participate via a live webcast. Stockholders must use their proxy cards to access the meeting. Following this, a corporate update will be presented by CEO Brett P. Monia at 5:30 p.m. ET, accessible to all interested parties. Details for participation and additional resources are available on Ionis' website.
Ionis Pharmaceuticals (Nasdaq: IONS) will host a live webcast on May 4, 2022, at 11:30 a.m. Eastern Time to discuss its first quarter financial results and update on pipeline and business progress. This event follows over 30 years of Ionis's leadership in RNA-targeted therapies, with three marketed medicines and a strong late-stage pipeline focusing on cardiovascular and neurological areas. Access the webcast and replay details at ionispharma.com.
Ionis Pharmaceuticals and AstraZeneca announced positive results from the ETESIAN Phase 2b study of ION449 (AZD8233), aimed at reducing cholesterol in patients with hypercholesterolemia. The study met its primary endpoint, achieving a 79% reduction in LDL-C levels, with both treatment doses (50mg and 90mg) showing significant efficacy. The trial also confirmed a reduction in PCSK9 levels by up to 94%. ION449 was well tolerated, and the results support further clinical development as a potential next-generation treatment for patients at high cardiovascular risk.
Biogen and Ionis Pharmaceuticals announced the Phase 1 study results of BIIB078, an investigational drug for C9orf72-associated ALS. The study, involving 106 participants, found that BIIB078 did not demonstrate any clinical benefit and failed to meet secondary efficacy endpoints. As a result, the clinical program for BIIB078 will be discontinued. Although well-tolerated, the study highlighted that the disease mechanism is more complex than initially hypothesized. Both companies remain committed to advancing ALS research and addressing this neurodegenerative disease.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced its participation in several upcoming investor conferences. Key events include:
- Stifel 2022 Virtual CNS Days on March 28, 2022
- Guggenheim Virtual Genomic Medicines and Rare Disease Day on April 1, 2022
- Needham 21st Annual Virtual Healthcare Conference on April 11, 2022
- Bank of America 2022 Healthcare Conference on May 11, 2022, in Las Vegas, NV
Ionis Pharmaceuticals has published positive Phase 2 results for donidalorsen, an investigational treatment for hereditary angioedema (HAE). The study showed a 90% reduction in angioedema attacks with 80 mg monthly doses compared to placebo, alongside significant improvement in quality of life. The treatment was well-tolerated with no serious adverse events noted. These findings support the ongoing Phase 3 study for donidalorsen, emphasizing Ionis' commitment to addressing unmet medical needs in HAE patients.
Ionis Pharmaceuticals (Nasdaq: IONS) announced it is accepting applications for the Janice Wiesman Young Investigator Grant Program, honoring Dr. Wiesman for her contributions to understanding transthyretin amyloidosis (ATTR). The program offers $50,000 annually for two years to U.S. researchers advancing ATTR knowledge, with applications due by April 4, 2022. The inaugural grants were awarded to Dr. Trejeeve Martyn and Dr. Jeremy Slivnick for their research on cardiac amyloidosis. March is also recognized as Amyloidosis Awareness Month, highlighting the disease's significance.
Ionis Pharmaceuticals (Nasdaq: IONS) will engage in a panel discussion focused on orphan neurological disease therapeutics at the upcoming Cowen 42nd Annual Health Care Conference. The event is scheduled for 9:10 a.m. ET on March 7, 2022. Interested parties can access a live webcast on the company's Investors & Media section of their website, with a replay available for a limited time. Ionis boasts over 30 years in RNA-targeted therapy, including three marketed medicines and a robust late-stage pipeline that emphasizes neurological and cardiometabolic franchises.
Ionis Pharmaceuticals reported strong financial results for 2021, exceeding guidance with total revenues of $810 million, driven by significant partner payments. The company has a solid cash position of $2.1 billion, enabling continued investment in R&D. Key achievements include collaborations with AstraZeneca on eplontersen and ongoing Phase 3 studies for multiple therapies. Positive Phase 2 results for olezarsen and donidalorsen were also announced. For 2022, Ionis expects revenue of over $575 million and a net loss of less than $275 million.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) will host a live webcast on February 24 at 11:30 a.m. ET to discuss its fourth quarter and full year 2021 financial results. The webcast will also cover the company's pipeline and business progress. Access the webcast and replay through the company's investor relations page. Ionis is a leader in RNA-targeted therapy, offering three marketed medicines and a robust late-stage pipeline focused on neurological and cardiometabolic diseases.
